Soulmates Ventures
Edit

Soulmates Ventures

https://www.soulmatesventures.com/
Last activity: 03.09.2026
Active
Sustainable venture capital fund accelerating entrepreneurs who build profitable and sustainable solutions for the future.
Portfolio
4
Mentions
45
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 4

DateNameWebsiteTotal RaisedLocation
03.03.2026Antiverseantiverse.io$18.84MUnited Kin...
12.01.2026FluoSphera...fluosphera.com$3.71MSwitzerlan...
23.10.2025Rightcharg...rightcharge.co.uk$3.76MUnited Kin...
14.08.2025Better Med...bettermedicine.ai$3.92MEstonia, ,...

Mentions in press and media 45

DateTitleDescription
03.09.2026Rightcharge raises £500K to scale fleet EV charging payments across EuropeUK EV charging payments startup Rightcharge has raised £500,000 in growth funding to expand across Europe and further develop its platform for managing fleet charging payments. The round was led by existing investor Soulmates Ventures, with...
13.03.2026100+ investors who already secured their tickets for this year’s EU-Startups Summit on May 7-8 in Malta!On May 7-8, the EU-Startups Summit will celebrate its 2026 edition at the iconic Mediterranean Conference Centre in Valletta, Malta. As one of Europe’s premier startup events, this gathering promises two days of networking, inspiration, and...
03.03.2026Antiverse secures $9.3M Series A for AI antibody platformUK-based Antiverse, a biotech company developing AI-designed therapeutic antibodies for hard-to-target disease targets, has closed a $9.3 million Series A round led by Soulmates Ventures, with participation from Innovation Investment Capita...
03.03.2026Antiverse Raises $9.3M in Series A FundingAntiverse, a Cardiff, Wales, UK-based AI-driven techbio company, raised $9.3M in Series A funding. The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures and existing investors DBW, Ka...
03.03.2026Antiverse: $9.3 Million Raised For AI-Driven Antibody Development Targeting Undruggable Disease TargetsAntiverse, an AI-driven techbio company specializing in de novo antibody design for challenging drug targets, has raised $9.3 million in Series A financing to accelerate the development of therapeutic antibodies aimed at historically undrug...
20.01.2026Soulmates Ventures Backs FluoSphera Rethinking Preclinical Drug DevelopmentWith Soulmates Ventures’ support, Fluosphera is building scalable, human-relevant preclinical models to reduce drug development failure Its multiplexed platform enables early, decision-grade insights across multiple interacting human tissue...
13.01.2026FluoSphera Secures €1.23M to Revolutionize Drug Discovery with Human-Relevant PlatformFluoSphera, a Swiss biotech firm, secured €1.23 million. This vital funding propels its advanced drug discovery platform. The patented multi-tissue system offers animal-free, human-relevant testing. It predicts drug effects with high accura...
12.01.2026FluoSphera Raises CHF 1.15M to Scale Human-Based Preclinical Platform Developing a new drug takes on average 10 to 15 years, and costs between $2 and $3 billion, according to Deloitte’s 2023 Pharmaceutical Innovation Report. Yet, despite these investments, over 90% of drug candidates still fail in clinical t...
12.01.2026Female-led Swiss BioTech FluoSphera secures €1.23 million to advance animal-free, human-relevant drug discoveryGeneva-based BioTech startup FluoSphera today announced that it has raised €1.23 million (CHF 1.15 million) in funding to make drug discovery faster, safer, and more human-relevant with its patented multi-tissue platform. The round was led ...
12.01.2026FluoSphera secures €1.23M to expand human-based preclinical platformFluoSphera, a Swiss biotech startup focused on drug safety and efficacy testing, has raised €1.23 million (CHF1.15 million) in funding. The round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In